Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Masitinib (AB1010)
Cat No.
CEI-0066
Description
Masitinib (AB1010) is a novel phenylaminothiazole-type tyrosine kinase inhibitor which can inhibit PDGFR-alpha, PDGFR-beta, KIT wild type, KIT V559D, KIT delta27(murine) with IC50 of 300 nM, 50 nM, 150 nM, 3 nM and 5 nM.
CAS No.
790299-79-5
Molecular Weight
498.64
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
PDGFR-alpha, PDGFR-beta, KIT(wild type), KIT(V559D), KIT(delta27)
Molecular Formula
C28H30N6OS
Chemical Name
N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
Solubility
DMSO 100 mg/mL Water
In vitro
Masitinib (AB1010) is a novel phenylaminothiazole-type tyrosine kinase inhibitor which can inhibit PDGFR-alpha, PDGFR-beta, KIT wild type, KIT V559D, KIT delta27(murine) with IC50 of 300 nM, 50 nM, 150 nM, 3 nM and 5 nM. In vitro, masitinib can inhibit POS, HMPOS, and COS31 cell lines with IC50 of 11.04 uM, 7.09 uM, and 9.74 uM. Masitinib can also cause dose-dependent HSA cell death.
In vivo
In dogs, masitinib causes dose-time dependent OSA cell death in vitro through initiation of caspase-mediated apoptosis. Combined use of masitinib with doxorubicin in the treatment of dogs with doxorubicin-resistant malignant lymphoma.
Download
Download Datasheet